<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>28109551</identifier>
<setSpec>1578-1852</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Martínez-Sesmero, José Manuel</dc:author>
<dc:author>Pasquau, Juan</dc:author>
<dc:author>Roldán, Celia</dc:author>
<dc:author>Poveda, José Luis</dc:author>
<dc:author>Hernández-Novoa, Beatriz</dc:author>
<dc:author>Rubio, Rafael</dc:author>
<dc:author>Pérez-Mitru, Alejandro</dc:author>
<dc:author>Ribera, Esteban</dc:author>
<dc:author>Sánchez-Rubio, Javier</dc:author>
<dc:description xml:lang="en">INTRODUCTION The objective of this study is to estimate the economic impact associated with the optimisation of triple antiretroviral treatment (ART) in patients with undetectable viral load according to the recommendations from the GeSIDA/PNS (2015) Consensus and their applicability in the Spanish clinical practice. METHODS A pharmacoeconomic model was developed based on data from a National Hospital Prescription Survey on ART (2014) and the A-I evidence recommendations for the optimisation of ART from the GeSIDA/PNS (2015) consensus. The optimisation model took into account the willingness to optimise a particular regimen and other assumptions, and the results were validated by an expert panel in HIV infection (Infectious Disease Specialists and Hospital Pharmacists). The analysis was conducted from the NHS perspective, considering the annual wholesale price and accounting for deductions stated in the RD-Law 8/2010 and the VAT. RESULTS The expert panel selected six optimisation strategies, and estimated that 10,863 (13.4%) of the 80,859 patients in Spain currently on triple ART, would be candidates to optimise their ART, leading to savings of €15.9M/year (2.4% of total triple ART drug cost). The most feasible strategies (&gt;40% of patients candidates for optimisation, n=4,556) would be optimisations to ATV/r+3TC therapy. These would produce savings between €653 and €4,797 per patient per year depending on baseline triple ART. CONCLUSION Implementation of the main optimisation strategies recommended in the GeSIDA/PNS (2015) Consensus into Spanish clinical practice would lead to considerable savings, especially those based in dual therapy with ATV/r+3TC, thus contributing to the control of pharmaceutical expenditure and NHS sustainability.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:subject>Tratamiento antirretroviral</dc:subject>
<dc:subject>Antiretroviral Therapy</dc:subject>
<dc:subject>Optimisation</dc:subject>
<dc:subject>Optimización</dc:subject>
<dc:subject>Gasto sanitario</dc:subject>
<dc:subject>Budget impact</dc:subject>
<dc:subject>Impacto presupuestario</dc:subject>
<dc:subject>Human immunodeficiency virus</dc:subject>
<dc:subject>Coste</dc:subject>
<dc:subject>Health Expenditures</dc:subject>
<dc:subject>Virus de la inmunodeficiencia humana</dc:subject>
<dc:subject>Cost</dc:subject>
<dc:date>2017 Jan 18 </dc:date>
<dc:title xml:lang="es">Impacto económico asociado a la implementación de las recomendaciones con grado de evidencia A-I del documento de consenso de GeSIDA/PNS (2015) relativas a la optimización del tratamiento antirretroviral en adultos infectados por virus de la inmunodeficiencia humana con carga viral suprimida en España.</dc:title>
<dc:title xml:lang="en">[Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan].</dc:title>
<dc:publisher>Enfermedades infecciosas y microbiologia clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
